Enhanced effects of osteoclastogenesis inhibition by curcumin-delivering heparin nanoparticles
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yun, Young-Pil | - |
dc.contributor.author | Kim, Sung Eun | - |
dc.contributor.author | Lee, Jae Yong | - |
dc.contributor.author | Kim, Hak-Jun | - |
dc.contributor.author | Choi, Sung-Wook | - |
dc.contributor.author | Song, Hae-Ryong | - |
dc.contributor.author | Park, Kyeongsoon | - |
dc.date.accessioned | 2021-11-16T01:40:16Z | - |
dc.date.available | 2021-11-16T01:40:16Z | - |
dc.date.issued | 2014-06 | - |
dc.identifier.issn | 1598-5032 | - |
dc.identifier.issn | 2092-7673 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/51441 | - |
dc.description.abstract | Curcumin has various pharmacological activities such as anti-inflammatory, antioxidant, antimicrobial and antitumor activity. However, its use has been limited due to its poor solubility in water and minimal systemic bioavailability. Thus, we developed curcumin-delivering heparin-based nanoparticles and evaluated the inhibition effects of osteoclastogenesis by curcumin-delivering heparin nanoparticles (Cur-HD NPs). Cur-HD NPs were dispersed well in aqueous solution by forming self-assembled nanoparticles and showed sustained release of curcumin. In vitro studies, HD NPs facilitated intracellular delivery of curcumin into macrophages and osteoclasts, and thus, Cur-HD NPs effectively inhibited osteoclastogenesis in a dose-dependent manner by suppressing tartrate-resistant acid phosphatase (TRAP) activity and TRAP-positive multinucleated cells as well as by reducing the expression of osteoclast marker genes (i.e., TRAP and nuclear factor of activated T cells cytoplasmic 1 (NFATc1)). Furthermore, Cur-HD NPs markedly stimulated apoptosis of osteoclasts. Therefore, we hope that Cur-HD NPs will be useful nanodrugs for the treatment of bone-related diseases. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | POLYMER SOC KOREA | - |
dc.title | Enhanced effects of osteoclastogenesis inhibition by curcumin-delivering heparin nanoparticles | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s13233-014-2082-1 | - |
dc.identifier.bibliographicCitation | MACROMOLECULAR RESEARCH, v.22, no.6, pp 647 - 656 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000338316700011 | - |
dc.citation.endPage | 656 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 647 | - |
dc.citation.title | MACROMOLECULAR RESEARCH | - |
dc.citation.volume | 22 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | curcumin | - |
dc.subject.keywordAuthor | heparin nanoparticles | - |
dc.subject.keywordAuthor | osteoclast | - |
dc.subject.keywordAuthor | osteoclastogenesis | - |
dc.subject.keywordAuthor | RANKL | - |
dc.subject.keywordPlus | NF-KAPPA-B | - |
dc.subject.keywordPlus | NECROSIS-FACTOR-ALPHA | - |
dc.subject.keywordPlus | RECEPTOR ACTIVATOR | - |
dc.subject.keywordPlus | DEOXYCHOLIC-ACID | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | ANTITUMOR-ACTIVITY | - |
dc.subject.keywordPlus | BONE METABOLISM | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | DIFFERENTIATION | - |
dc.relation.journalResearchArea | Polymer Science | - |
dc.relation.journalWebOfScienceCategory | Polymer Science | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.